Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | CASP6 | P55212 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CASP4 | P49662 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | CASP9 | P55211 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060750 | 0.91 | SIRT2 (0.56) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL30663251 | 0.86 | GAA (0.57) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL1231915 | 0.86 | GAA (0.57) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL20162398 | 0.81 | GRIN1 (0.54) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL28025254 | 0.81 | SIRT2 (0.49) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL30062486 | 0.81 | CASP6 (0.51) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL8127050 | 0.81 | SIRT2 (0.49) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL8128306 | 0.81 | ATAD2 (0.61) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL2061250 | 0.80 | SIRT2 (0.57) | SIRT2ALDH1A1GAACASP6CASP1 | |
| SCHEMBL14049826 | 0.79 | GRIN1 (0.57) | SIRT2GAACASP6CASP1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| EP-4093400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | The Trustees of Princeton University (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2021151062-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERISTY (US) | 2021-07-29 | — | — | WO | disclosed |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| CN-106983751-B | Bicyclic substituted uracils and their use | 拜耳医药股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1049692-A1 | NOVEL BICYCLENE-SUBSTITUTED OXAZOLIDINONES | Bayer Aktiengesellschaft (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037641-A1 | NOVEL BICYCLENE-SUBSTITUTED OXAZOLIDINONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | SIRT2 31/4885ALDH1A1 956/4885GAA 2636/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | SIRT2 31/4885ALDH1A1 956/4885GAA 2636/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | SIRT2 1161/4885ALDH1A1 437/4885GAA 517/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | SIRT2 1161/4885ALDH1A1 437/4885GAA 517/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | SIRT2 1161/4885ALDH1A1 437/4885GAA 517/4885 |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | SIRT2 31/4885ALDH1A1 956/4885GAA 2636/4885 |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | SIRT2 378/4885ALDH1A1 13/4885GAA 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.